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Reverse cholesterol transport (RCT) is an antiathero-
genicprocess inwhichexcessivecholesterol frompe-
ripheral tissues is transported to the liver and finally
excreted fromthebodyvia thebile.Thenuclear recep-
tor liver receptorhomolog1 (LRH-1) drivesexpression
of genes regulating RCT, and its activity can bemodi-
fiedbydifferentposttranslationalmodifications.Here,
we show that atherosclerosis-prone mice carrying
a mutation that abolishes SUMOylation of LRH-1 on
K289R develop less aortic plaques than control litter-
mates when exposed to a high-cholesterol diet. The
mechanism underlying this atheroprotection involves
an increase in RCT and its associated hepatic genes
and is secondary to a compromised interaction of
LRH-1 K289R with the corepressor prospero homeo-
box protein 1 (PROX1). Our study reveals that the
SUMOylation statusof a single nuclear receptor lysine
residue can impact the development of a complex
metabolic disease such as atherosclerosis.
INTRODUCTION
Atherosclerosis is a disease characterized by excessive
cholesterol accumulation in vessel walls. It evolves from a com-
plex interplay between hypercholesterolemia, dyslipidemia, and
chronic inflammation and encompasses several tissues and
organs (Weber and Noels, 2011). Rupture of an atherosclerotic
plaque may lead to a myocardial infarction or stroke, two of
the primary causes ofmorbidity andmortality in theworld (Weber
and Noels, 2011).
Liver receptor homolog 1 (LRH-1 or NR5A2) is a member of the
NR5A subfamily of nuclear receptors (NRs) that binds as amono-
mer to its response elements (Fayard et al., 2004). The transcrip-Celltional activity of LRH-1 is governed by multiple factors, including
the binding of ligands and posttranslational modifications, which
together define its interaction with transcriptional coregulators
(Fernandez-Marcos et al., 2011; Lee and Moore, 2008). LRH-1
is highly expressed in tissues of the enterohepatic axis, where it
has diverse molecular and physiological functions (Fayard et al.,
2004) ranging from local glucocorticoidproduction in the intestine
(Coste et al., 2007) to glucose sensing in the liver (Oosterveer
et al., 2012). Interestingly, one of the first described LRH-1 target
genes is scavenger receptor B type 1 (Scarb1) (Schoonjans et al.,
2002), a gene that is expressed in many tissues and plays
important functions in reverse cholesterol transport (RCT), an
antiatherogenic process in which excessive cholesterol from
peripheral tissues is transported to the liver and finally excreted
via the bile (Rosenson et al., 2012). Although several other LRH-
1 target genes involved in cholesterol metabolism have been
identified, including carboxl ester lipase (Cel) (Fayard et al.,
2003), ATP binding cassette member subfamily G5 (Abcg5),
Abcg8 (Freeman et al., 2004), and apolipoprotein M (Apom)
(Venteclef et al., 2008), so far no study has demonstrated that
LRH-1 activity is critical for proper RCT or atherogenesis.
LRH-1 is targeted for SUMOylation by E3-SUMO ligases at
several lysine residues, and this conserved reversible posttrans-
lational modification affects its transcriptional activity (Chalkia-
daki and Talianidis, 2005; Lee et al., 2005; Talamillo et al.,
2013; Venteclef et al., 2010; Ward et al., 2013). SUMOylation of
human LRH-1 is considered to attenuate its transcriptional activ-
ity, yet the mechanistic basis underlying this repression is poorly
understood. Although one study reported that the SUMOylated
form of LRH-1 is sequestered into promyelocytic leukemia
(PML) protein bodies (Chalkiadaki and Talianidis, 2005), another
study proposed that SUMO modification of LRH-1 stabilizes the
recruitment of the transcriptional nuclear receptor corepressor 1
and histone deacetylase 3 (NCoR1/Hdac3) corepressor complex
through its association with G protein pathway suppressor 2
(GPS2) (Venteclef et al., 2010).
In this study, we demonstrate that mice carrying a mutation on
lysine 289 of LRH-1 (Lrh1 K289R mice) display reduced LRH-1Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inc. 603
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Figure 1. Non-SUMOylatable LRH-1 K289R Displays Increased Reporter Activity and Impaired SUMOylation In Vitro
(A) Schematic overview of LRH-1 highlighting the lysine residues that were mutated. DBD, DNA binding domain; FTZ, fushi tarazu homology domain; LBD, ligand
binding domain; AF2, activation function 2 domain.
(B) Luciferase assay performed in HEK293T cells that were cotransfected with a pGL3::(LRHRE)5-TK-LUC and a pCMV plasmid coding for LRH-1 WT or the
outlined mutant constructs. n = 3. The experiment was replicated three times.
(C) Immunoprecipitation of V5-tagged LRH-1 to detect the SUMOylated band of LRH-1 (arrowheads). HEK293T cells were transfected with pCMV-V5::LRH-1WT
or pCMV-V5::LRH-1 K289R, pCMV::PIAS3, and/or pcDNA-HA::SUMO-1-HA. The experiment was replicated at least three times.
(D) Immunoprecipitation of V5-tagged LRH-1 to detect the SUMOylated band of LRH-1 in HEK293T cells that were transfected with pCMV-V5::LRH-1 (WT or
K289R) and pCMV-FLAG::SENP1. The experiment was replicated at least three times.
(E) Residues adjacent to K289 are required for SUMOylation and function of LRH-1 activity. Luciferase assay was performed in HEK293T cells that were
cotransfectedwith a pGL3::(LRHRE)5-TK-LUC and pCMVplasmid coding for LRH-1WT or the outlinedmutant constructs. n = 3 from three separate experiments.
(F) Immunoprecipitation of V5-tagged LRH-1 to detect SUMOylation of the different mutant constructs used in (E).
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to Lrh-1 WT, as determined by ANOVA and Bonferonni post hoc or Student’s
t test. Arrowheads, LRH-1*SUMO-1 band; x, short exposure; z,long exposure.
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Role of LRH-1 SUMOylation in AtherosclerosisSUMOylation and increased expression of genes regulating
cholesterol transport. When crossbred to atherosclerosis-prone
low-density lipoprotein receptor (Ldlr) knockout mice, Ldlr/
Lrh-1 K289R mice show improved RCT and diminished athero-
sclerosis development in comparison to control mice. Mechanis-
tically, this effect is attributed to the specific loss of interaction of
the mutated form of LRH-1 with the corepressor PROX1, thereby
increasing the expression of LRH-1 target genes involved in RCT.
RESULTS
Non-SUMOylatable LRH-1 K289R Displays Increased
Transcriptional Activity In Vitro
The murine LRH-1 protein has several lysine (K) residues that
could be SUMOylated. They are located in the DNA binding
domain, hinge region, or ligand binding domain (Figure 1A). On
the basis of previous studies (Lee et al., 2005), we mutated the
most relevant K residues to non-SUMOylatable arginines (R)
and analyzed their potential to trans-activate a heterologous
LRH-1 reporter by transient transfection assays (Figure 1B).604 Cell Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier InInterestingly, the K289R mutation displayed the highest tran-
scriptional activity, whereas the remaining K mutations (K173R,
K213R, or K329R) had neither an effect as single mutations nor
an additive effectwhenmutated together with K289R (Figure 1B).
Next, we analyzed whether the enhanced activity of LRH-1
K289R was also associated with a reduction in the SUMOylation
status. Human embryonic kidney 293T (HEK293T) cells trans-
fected with either LRH-1 wild-type (WT) or LRH-1 K289R were
cotransfected with either PIAS3 SUMO ligase alone or in combi-
nation with SUMO-1 substrate. Basal LRH-1 WT SUMOylation
was clearly detectable, whereas it was nearly undetectable
in LRH-1 K289R (Figure 1C). Cotransfection with PIAS3 and
SUMO-1 slightly increased SUMOylation of LRH-1 WT (Fig-
ure 1C). Notably, LRH-1 K289R SUMOylation remained low after
PIAS3 and SUMO-1 cotransfection, showing that mutating a sin-
gle K residue can affect the total SUMOylation status of the tran-
scription factor (Figure 1C). Moreover, cotransfection of LRH-1
WT or LRH-1 K289R with the isopeptidase sentrin/SUMO-spe-
cific protease 1 (SENP1) efficiently removed the SUMO modifi-
cation from only LRH-1 WT (Figure 1D). The SUMO acceptorc.
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Figure 2. The LRH-1 SUMOAcceptorMotif Is Conserved in Vertebrates, andMutation of Its Lysine Triggers Activation of Cholesterol Homeo-
stasis Genes In Vivo
(A) Alignment of the amino acid sequence surrounding the murine LRH-1 K289 residue with other species. The blue-lined box highlights the aligned amino acids
homologous to the SUMO acceptor motif, and the gray shading marks the sequences with an intact SUMO acceptor sequence.
(B) Protein alignment of LRH-1 (NR5A2) with other monomeric NR showing conserved sequences surrounding the LRH-1 K289 residue. Green, high homology;
red, low homology.
(C) Overview of the genomic and protein sequence surrounding the K289R mutation. Mutation of a single nucleotide (AAG/ AGG) at genomic level leads to
K289R mutation of the translated protein.
(D) Venn diagram depicting the number of genes that are significantly up- or downregulated in Lrh-1hep/ (n = 8) in comparison to Lrh-1hep+/+ (Oosterveer et al.,
2012) (n = 8) as well as Lrh-1 K289R (n = 7) in comparison to Lrh-1 WT (n = 7) mice.
(E) Heatmap displaying the expression of selected LRH-1 target genes in the corresponding genotypes (n = 4 per genotype).
(F) Hepatic expression of genes that regulate cholesterol homeostasis in Lrh-1 WT (n = 8) and Lrh-1 K289R (n = 9) mice.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to Lrh-1 WT, as determined by Student’s t test. See also Figures S1
and S2.
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Role of LRH-1 SUMOylation in AtherosclerosismotifJ-K-x-E is found in many SUMOylated proteins. Although
the lysine residue can be targeted for SUMOylation, the adjacent
hydrophobic (J) and acidic glutamate (E) residues are also
necessary tomediate the conjugation with the SUMOE2 enzyme
Ubc9 (Bernier-Villamor et al., 2002). Mutation of these two sites
(I288A and E291V) also increased LRHRE-driven reporter activ-
ity (Figure 1E) and reduced LRH-1 SUMOylation (Figure 1F),
showing that not only the lysine but also an intact SUMOacceptor
motif is crucial for the SUMO-dependent function of LRH-1.
LRH-1 K289R Activates Selected Target Genes In Vivo
To understand the relevance of this particular SUMO acceptor
lysine residue, we carried out comparative alignment studies.
Alignment of the amino acids surrounding the murine LRH-1
K289 with other species demonstrated that this particularCellSUMO acceptor motif is highly conserved in vertebrates but
not in the chordate lancelet (Branchiostoma floridae), sea urchin
(Strongylocentrotus purpuratus), fruit fly (Drosophila mela-
nogaster), or roundworm (Caenorhabditis elegans; Figures 2A;
Figure S1A available online). However, homologous proteins in
C. elegans and D. melanogaster have other sites that can be tar-
geted for SUMOylation (Talamillo et al., 2013; Ward et al., 2013).
Next, we compared the murine LRH-1 protein sequence with
other monomeric NRs with special focus on the highly variable
and intrinsically disordered hinge region (Krasowski et al.,
2008). Besides the close homolog NR5A1 (SF-1), only the reti-
noic-acid-receptor-related orphan receptors (RORs:NR1F1,
NR1F2, and NR1F3) displayed somewhat homologous hinge
regions (Figure S1B). Closer alignment of LRH-1 with NR5A1
and the three RORs showed that only NR1F1 and NR1F2 containMetabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inc. 605
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Figure 3. LRH-1 K289R Protects against
Atherosclerosis Progression
(A) Quantification of aortic plaque area in Ldlr/
Lrh-1 WT (LL-WT) or Ldlr/ Lrh-1 K289R (LL-
K289R) mice. n = 11 per genotype.
(B) Quantification of the cholesterol content in
aortic lipid extracts of LL-WT (n = 9) and LL-K289R
(n = 8) mice.
(C) Representative aortas of LL-WT and LL-K289R
mice stained with Oil-Red O.
(D) Quantification of cholesterol and triglyceride
contents in hepatic lipid extracts of LL-WT and
LL-K289R mice. n = 6 per genotype.
(E) Representative images of hematoxylin and
eosin and Oil-Red O (ORO) staining of hepatic
sections of LL-WT and LL-K289R mice. The white
scale bar represents 200 mm, and the black scale
bar represents 50 mm.
Data are represented as means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 relative to LL-WT, as
determined by Mann-Whitney U or Student’s
t tests. See also Figure S3.
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Role of LRH-1 SUMOylation in Atherosclerosisthe conserved SUMO acceptor motif (Figure 2B). These bio-
informatic data suggest that SUMOylation of this site is specific
for a very small subset of NRs and highlights the functional
importance of the hinge region in these selected NRs.
To analyze the physiological impact of the K289R mutation on
LRH-1 function in vivo, we generated a knockin mouse line con-
taining the K289R mutation Lrh-1 K289R (Figures 2C and S2A).
The offspring of Lrh-1 K289R breeders were born under normal
Mendelian and sex ratios, and no apparent dysmorphic pheno-
type could be observed in these mice (data not shown). The
mutation did not affect the expression of LRH-1 in the liver in
comparison to Lrh-1 WT and hepatocyte-specific Lrh-1hep+/+
mice (Figure S2B). Then, we performed microarray analyses on
livers in order to compare the transcriptome of hepatocyte-spe-
cific Lrh-1hep/ (Oosterveer et al., 2012) and Lrh-1 K289R mice
to their corresponding controls. Only 57 of the 244 genes
(23.4%) whose expression was decreased in Lrh-1hep/ mice
were induced in Lrh-1 K289R mice (Figure 2D and Table S1).
Several of the established LRH-1 target genes that are reduced
in Lrh-1hep/ mice were oppositely regulated in Lrh-1 K289R
mice (Figure 2E). Intriguingly, most of the selected hepatic
LRH-1 target genes involved in cholesterol metabolism were
increased in Lrh-1 K289R in comparison to Lrh-1 WT mice, as
determined by qPCR analyses (Figure 2F). Although hepatic
expression of Cyp8b1 was nearly absent in hepatocyte-specific
Lrh-1hep/mice (Mataki et al., 2007), it was onlymildly enhanced
in Lrh-1 K289Rmice (Figure 2F). This was reflected in the compo-
sition of bile acids in the gallbladder. Although the total bile acid
content did not differ, Lrh-1 K289R mice had slightly increased
tauro-conjugated cholic acid (tCA) and less tauro-conjugated
muricholic acid (tMCA) (Figure S2C). Altogether, these data
show that LRH-1 K289R exhibits increased transcriptional activ-
ity on a selected subset of LRH-1 target genes and cannot be
described as a global constitutive active LRH-1 form.
LRH-1 K289R Protects against Atherosclerosis
Development
Given that many of the genes affected in Lrh-1 K289R mice are
involved in cholesterol homeostasis, we hypothesized that606 Cell Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier InLRH-1 K289Rmay affect cholesterol metabolism, and hence hy-
percholesterolemia-driven diseases, such as atherosclerosis. To
study the role of LRH-1 K289R in atherosclerosis, we crossbred
Lrh-1 WT and Lrh-1 K289R mice to atherosclerotic-prone Ldlr
knockout mice in order to generate Ldlr/ Lrh-1 WT (LL-WT)
or Ldlr/ Lrh-1 K289R (LL-K289R) mice. Then, 8-week-old LL-
WT or LL-K289R mice were subjected to a high-cholesterol
diet (HCD) for 14 weeks. Body and liver weight (Figures S3A
and S3B), and also gross morphology of other organs, were
similar between the different genotypes (data not shown).
Notably, en face plaque analyses of the thoraco-abdominal aorta
demonstrated that LL-K289R mice developed significantly less
atherosclerotic plaques than LL-WT mice and also accumulated
less cholesterol in their aortas (Figures 3A–3C). Advanced pla-
que analyses of the aortic sinus stained for collagen imaging
revealed no changes in necrotic core size, cap thickness, or
collagen content in LL-K289R in comparison to LL-WT mice
(Figures S3C–S3E). Total plasma cholesterol did not differ be-
tween the mice, and plasma triglyceride levels were only slightly
reduced before administering the HCD andwere not significantly
changed upon HCD feeding (Figures S3F and S3G). Although no
changes in triglyceride content were observed in the lipoprotein
fractions, a small reduction in the cholesterol content of the
low-density lipoprotein subfraction of LL-K289R mice could be
noticed (Figures S3H and S3I). Furthermore, hepatic triglyceride
content was not changed in overnight fasted LL-K289R mice,
whereas cholesterol content was only slightly increased (Fig-
ure 3D). Stainings of liver cryosections showed no apparent dif-
ference in neutral lipid content and cellular morphology between
the two genotypes (Figure 3E). These data demonstrate that
LL-K289R mice develop less atherosclerosis, possibly as a
consequence of improved RCT.
To assess a potential contribution of macrophages in the
observed phenotype, we measured Lrh-1 in isolated thioglyco-
late-elicited peritonealmacrophages. In comparison to its expres-
sion in the liver, Lrh-1 was barely detectable in macrophages
under the conditions analyzed (Figure S4A; bioGPS Lrh-1 expres-
sion pattern, http://biogps.org/#goto=genereport&id=26424).
Furthermore, treatment with acetylated LDL (acLDL) to triggerc.
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Figure 4. Improved Reverse Cholesterol Transport and Biliary Sterol Excretion in LL-K289R Mice
(A) Hepatic expression of genes affecting cholesterol metabolism in LL-WT and LL-K289R mice. n = 9 per genotype.
(B) Intestinal expression of genes affecting cholesterol metabolism in LL-WT and LL-K289R mice. Duod, duodenum; Jejun, jejunum. n = 9 per genotype.
(C–H) LL-WT and LL-K289Rmice were injected with 3H-cholesterol loaded LL-WTmacrophages. Detection of 3H-tracer in plasma (C), fecal cholesterol (Chol; D),
fecal bile acids (BA; E), liver (F), bile cholesterol fraction (G), and bile BA fraction (H). n = 10 LL-WT; n = 12 LL-K289R.
(I–L) Bile excretion (I) and biliary secretion rates of Chol (J), BA (K), and phospholipids (PL; L). n = 10 per genotype.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to LL-WT, as determined by Mann-Whitney U or Student’s t tests. See also
Figure S4.
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Role of LRH-1 SUMOylation in Atherosclerosisfoam cell formation or lipopolysaccharide (LPS) in order to eval-
uate the inflammatory response did not trigger any significant
difference in acetylated LDL accumulation, Scarb1 expression,
or inflammatory markers between Lrh-1 WT and K289R macro-
phages (Figures S4B–S4H), suggesting that the effects on aortic
lipid accumulation are not likely related to differential macrophage
function.
LRH-1 K289R Protects against Atherosclerosis by
Promoting RCT
Intrigued by the marked decrease of atherosclerotic lesions in
LL-K289R mice and the increased expression of genes involved
in hepatic cholesterol homeostasis in Lrh-1 K289R mice (Fig-
ure 2F), we analyzed the expression of genes involved in RCT
in the liver. Notably, hepatic expression of Abca1, Abcg5,
Abcg8, Apoe, and Scarb1 was significantly increased in LL-
K289R in comparison to LL-WT mice (Figure 4A). Given that
many of these genes are also expressed in the intestine
and contribute to whole-body cholesterol homeostasis, we
analyzed their expression pattern in the duodenum, jejunum,
and ileum. Surprisingly, none of these transcripts was
increased in any of the three intestinal sections (Figure 4B).CellMoreover, microarray analyses of jejunal sections from Lrh-1
K289R and Lrh-1 WT mice did not display differential expres-
sion of cholesterol and lipoprotein regulators that are ex-
pressed in livers and intestine (Figure S4I), indicating that
LRH-1 K289R specifically induces the expression of cholesterol
transport regulators in the liver.
To analyze whether the increased expression of RCT genes
has physiological consequences, we performed in vivo macro-
phage-to-feces RCT and biliary flux studies. In vivo RCT analysis
was performed by injecting peritoneal macrophages that were
loaded with [3H]-cholesterol (3H tracer) ex vivo into recipient
LL-K289R and LL-WT mice. 3H-tracer counts were significantly
increased in the fecal cholesterol fraction of LL-K289R in com-
parison to LL-WT mice, whereas no major differences were
observed in the fecal bile acid pool or the plasma, hepatic, or
biliary pools (Figures 4C–4H). Furthermore, gallbladder cannula-
tion revealed that bile flow was increased in LL-K289R in com-
parison to LL-WT mice (Figure 4I). In line with the increased
bile flow, biliary cholesterol, bile acids, and phospholipids excre-
tion were also enhanced in LL-K289R in comparison to LL-WT
mice (Figures 4J–4L). These data establish LRH-1 K289R as a
potent mediator of bile secretion and RCT in vivo.Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inc. 607
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Figure 5. Liver-Specific Lrh-1 Knockout Mice Do Not Develop More Atherosclerosis
(A) Quantification of aortic plaque area in Ldlr/ Lrh-1hep+/+ (Ld-WT, n = 12) or Ldlr/ Lrh-1hep/ (Ld-LKO, n = 11) mice.
(B) Representative aortas of Ld-WT and Ld-LKO mice stained with Oil-Red O.
(C) Hepatic expression of genes affecting cholesterol metabolism in Ld-WT and Ld-LKO mice. n = 9 per genotype.
(D–I) Ld-WT and Ld-LKOmice were injected with 3H-cholesterol loaded Ld-WTmacrophages. Detection of 3H tracer in plasma (D), fecal cholesterol (E), fecal BA
(F), liver (G), bile Chol fraction (H), and bile BA fraction (I). n = 13 Ld-WT; n = 10 Ld-LKO.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to LL-WT, as determined by Student’s t test. See also Figure S5.
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Role of LRH-1 SUMOylation in AtherosclerosisLiver-Specific Lrh-1 Knockout Mice Do Not Develop
Increased Atherosclerosis
Even though the transcriptome and targeted gene expression
analyses argue against Lrh-1 K289R as a simple constitutively
active form of LRH-1 (Figures 2D–2F), we nevertheless explored
whether the hepatocyte-specific Lrh-1hep/micewould yield an
opposite phenotype on RCT and atherosclerosis development.
Therefore, we crossbred hepatocyte-specific Lrh-1hep/ with
Ldlr/ mice in order to generate Ldlr/ Lrh-1hep+/+ (Ld-WT) or
Ldlr/ Lrh-1hep/ (Ld-LKO) mice and fed them an HCD for
12 weeks. Body and liver weight did not differ between the geno-
types (Figures S5A and S5B). Interestingly, Ld-LKO did not
develop more atherosclerotic lesions than Ld-WT mice (Figures
5A and 5B), although the expression of the RCT regulators (Fig-
ure 5C) and binding of LRH-1 to the Abcg5/Abcg8 intergenic
promoter (Freeman et al., 2004) (Figure S5C) was significantly
lower in the Ld-LKO liver. Moreover, in vivo RCT analysis demon-
strated an increased fecal sterol content in Ld-LKO mice, which
could explain why these mice do not develop more atheroscle-
rotic lesions (Figures 5D–5I). The increase of fecal sterols in
Lrh-1hep/mice most likely stems from the compromised intes-
tinal sterol absorption, which was previously reported to be the
consequence of reduced Cyp8b1 in the liver shifting the bile
acid pool toward more hydrophilic bile acids (Figure 5C) (Mataki
et al., 2007; Out et al., 2011).
Compromised Binding of LRH-1 K289R with the
Corepressor PROX1 Derepresses Hepatic RCT Genes
Several corepressors have been reported to fine-tune the activity
of LRH-1 in a context specific manner. In the liver, corepressors
such as small heterodimer partner (SHP or NR0B2) and prospero
homeobox protein 1 (PROX1) as well as the NCOR1/HDAC3
corepressor complex can repress LRH-1 activity (Goodwin608 Cell Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inet al., 2000; Lee and Moore, 2002; Lu et al., 2000; Qin et al.,
2004; Venteclef et al., 2010). To test the assumption that LRH-1
SUMOylation affects the interaction of LRH-1with potential core-
pressors, we carried out coimmunoprecipitation experiments in
HEK293T cells transfected with LRH-1 WT or LRH-1 K289R in
the presence of the corepressor SHP, PROX1, or NCOR1. Sur-
prisingly, we observed that the interaction between LRH-1 and
PROX1was lost ormuchweaker when LRH-1 K289Rwas ectop-
ically expressed (Figure 6A), whereas no difference in interaction
was observed with SHP or detected with NCOR1 (data not
shown). This would suggest that optimal PROX1-LRH-1 interac-
tionmay at least require transient SUMOylation of K289 of LRH-1
WT. To assess this possibility, we coexpressed the isopeptidase
SENP1 in order to enzymatically remove SUMO from its
substrates. SENP1 robustly reduced the interaction between
LRH-1 WT and PROX1, supporting the hypothesis that the
SUMOylation status affects the interaction (Figure 6B), which
might be direct or be mediated by a third partner. Interestingly,
the weaker interaction observed between PROX1 and LRH-1
K289R was further reduced by addition of SENP1, suggesting
that other SUMOylatable sites in the protein complex may
enhance the interaction between the two proteins (Figure 6B).
Given that loss of binding to the corepressor PROX1 would pro-
vide a mechanistic basis for explaining the enhanced activity
of LRH-1 K289R, we next explored whether differential Prox1
expression between liver and intestine could explain the absence
of effects on intestinal RCT genes in Lrh-1 K289R mice (Fig-
ure 4B). Interestingly, Prox1 mRNA was almost undetectable
in the small intestine and only marginally expressed in the colon
in comparison to liver (Figure 6C; bioGPS Prox1 expression
pattern, http://biogps.org/#goto=genereport&id=26424), thus
most likely contributing to the differential expression of RCT
genes between liver and intestine.c.
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Figure 6. Compromised Binding of LRH-1 K289R with Prox1 Derepresses Hepatic RCT Genes
(A) LRH-1/Prox1 CoIP in HEK293T cells overexpressing V5-tagged LRH-1 (WT or K289R) and FLAG-tagged Prox1. The experiment was replicated at least three
times.
(B) LRH-1/Prox1 CoIP in HEK293T cells overexpressing V5-tagged LRH-1 (WT or K289R), FLAG-tagged Prox1, and FLAG-tagged SENP1. The experiment was
replicated three times.
(C) Comparative Prox1 expression in liver, duodenum (Duod), jejunum (Jejun), ileum, and colon of LL-WT and LL-K289R mice. n = 9 per genotype.
(D) Expression of Scarb1, Abcg5, Abcg8, Abca1, and Abcg1 in Lrh-1hep/ primary hepatocytes that were infected or transfected with LRH-1 (WT or K289R) and
Prox1. n = 3. The experiment was replicated with three batches of primary cells.
(E) LRH-1/Prox1 CoIP in primary hepatocytes that were infected or transfected with V5-tagged LRH-1 (WT or K289R) and FLAG-tagged Prox1. n = 2 from
independent batches of primary hepatocytes.
(F and G) Effect of overexpression (F) and small-interfering-RNA-mediated silencing (G) of Prox1 in WT primary hepatocytes n = 3. The experiment was replicated
with two batches of primary cells.
(H) Model showing how LRH-1WT and LRH-1 K289R regulate the expression of key genes controlling hepatic cholesterol transport and its consequence on RCT
and atherosclerosis. S, SUMO-1.
Data are represented as means ± SEM. *p < 0.05 and **p < 0.01 relative to non-Prox-1-transfected controls, as determined by Student’s t test. See also
Figure S6.
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Role of LRH-1 SUMOylation in AtherosclerosisTo study the molecular effect of the PROX1-LRH-1 interaction
in more detail, we decided to use primary hepatocytes. Notably,
both Lrh-1 and Prox1 transcripts were reduced to 25% of their
expression in whole livers but were clearly detectable (Fig-
ure S6A). We isolated primary hepatocytes from Lrh-1hep/
mice and infected them with an adenovirus containing
the LRH-1 WT or K289R followed by ectopic expression
of PROX1. Interestingly, while expression of Abcg1 was not
affected or rather increased in cells overexpressing PROX1,Cellthe expression of Scarb1, Abcg5, and Abcg8 was diminished
in cells in which LRH-1 WT, but not LRH-1 K289R, was reconsti-
tuted (Figures 6D and S6B), demonstrating that the repressive
function of PROX1 on LRH-1 activity depends on an intact
LRH-1 K289 SUMOylation site. Furthermore, LRH-1 K289R
failed to bind PROX1 in transfected primary hepatocytes,
whereas LRH-1 WT/PROX1 interaction was intact (Figure 6E),
demonstrating that the LRH-1/PROX1 complex can assemble
in vitro and ex vivo. To assess whether we could mimic the effectMetabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inc. 609
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Role of LRH-1 SUMOylation in Atherosclerosisof LRH-1/PROX1 interaction in a physiologically relevant cell
model, we next overexpressed or silenced Prox1 in WT pri-
mary hepatocytes. While overexpression of Prox1 reduced the
expression of the RCT regulators (Figure 6F), silencing of Prox1
had the opposite effect (Figure 6G). Altogether, our data suggest
that SUMOylated LRH-1 WT recruits the corepressor PROX1
and hence is unable to selectively activate the transcription of
important cholesterol receptors and transporters (Figure 6H). If
SUMOylation of LRH-1 is defective as in our LRH-1 K289R
mutant, then the PROX1-mediated repression is weakened or
lost, thereby facilitating the induction of RCT genes and dimin-
ishing the progression of atherosclerosis (Figure 6H).
DISCUSSION
Posttranslational modification by SUMO affects the function
of a large number of nuclear proteins, including NRs (Geiss-
Friedlander and Melchior, 2007; Treuter and Venteclef, 2011).
Although various NRs have emerged as reversible SUMO targets
modulating almost every aspect of NR function in cell models,
very few studies have established in vivo functional roles of NR
SUMOylation in health or disease. This is rather surprising given
the prominent role of NRs in the pathogenesis of diseases
and the repressive imprint of SUMOylation on NR activity. In
this study, we have generated a mouse model harboring a
K289R mutation that strongly affects LRH-1 SUMOylation and
function. We demonstrate that loss of SUMOylation by mutating
the critical lysine acceptor site in the LRH-1 protein is sufficient to
protect mice against the development of a chronic metabolic
disease such as atherosclerosis. More importantly, we provide
evidence that the beneficial effect on atherosclerosis is caused
by enhancing the transcription of hepatic RCT genes, such as
Abca1, Abcg5, Abcg8, and Scarb1, without any involvement of
gut- or macrophage-specific RCT genes. These findings are
consistent with a recent study in Drosophila showing that
SUMOylation of the LRH-1 homolog Ftz-f1 affects the expres-
sion of the scavenger receptor Snmp1, which is required for
cellular cholesterol uptake and subsequent steroid synthesis
(Talamillo et al., 2013), suggesting that LRH-1 SUMOylation
may impact on a similar physiologically conserved pathway.
Alignment of the protein sequence of LRH-1with other NRs re-
vealed that, aside from SF-1, only members of the ROR family
have a hinge region that is comparable to that of LRH-1 (Fig-
ure 2B). Although in SF-1, mutation of two conserved SUMO
acceptor lysine residues in the hinge region leads to a striking
developmental phenotype in mice, characterized by inappro-
priate sonic hedgehog signaling and impaired endocrine tissue
development (Lee et al., 2011a), our study shows that disruption
of only one of these conserved SUMO sites in LRH-1 has a sig-
nificant impact on adult homeostasis and protects against the
development of a chronic disease. Surprisingly, SUMOylation
of the homologous motif in RORa seems to activate instead
of repressing its transcriptional activity (Hwang et al., 2009);
however, its physiological properties have not been reported.
These studies collectively indicate that SUMOylation of the hinge
region has profound functional consequences among a very
small subset of NRs.
The mechanistic features by which SUMO modulates the ac-
tivity of NRs vary considerably and can range from interference610 Cell Metabolism 20, 603–613, October 7, 2014 ª2014 Elsevier Inwith- to promotion of protein-protein interactions or alternatively
competition with other PTMs (Geiss-Friedlander and Melchior,
2007; Jentsch and Psakhye, 2013). Our data suggest a role for
LRH-1 SUMOylation in promoting protein-protein interactions.
This finding is in line with previous studies showing that
SUMOylation of LRH-1 K224, the human lysine residue corre-
sponding to mouse LRH-1 K289, binds to a transcriptional core-
pressor complex consisting of NCOR1, HDAC3, and GPS2 and
regulates the expression of acute phase response genes in hu-
man hepatoma cells (Venteclef et al., 2010). Interestingly, this
study further demonstrated that mouse LRH-1 binding to the
haptoglobin promoter was reduced in Sumo1 knockout in com-
parison to WT livers. In our study, we reveal an unanticipated
mechanism by demonstrating that LRH-1 K289R fails to bind
another corepressor (i.e., PROX1), and we furthermore show
that this impacts on the RCT genes, ultimately leading to
enhanced bile flow and atheroprotection. The study by Venteclef
et al. (2010), along with our work, propose that SUMOylation of a
single K residue of LRH-1 promotes the recruitment of specific
corepressor complexes. Importantly, our data demonstrate
that the effect of LRH-1 SUMOylation depends on tissue-spe-
cific corepressor interaction.
The physiological stimuli and timing that affect LRH-1
SUMOylation in the liver are unknown. In primary granulosa
cells, SUMO-driven sequestration of LRH-1 into nuclear bodies
is abruptly reversed by cAMP and results in the induction
of LRH-1 target genes (Yang et al., 2009). Intriguingly, this is
accompanied by a robust reduction of the Ubc9 and Pias3
genes, which are part of the SUMO conjugation machinery.
Conversely, expression of the SUMO-specific isopeptidase
Senp2 was increased. Although the crosstalk with the cAMP
signaling has not been evaluated in the context of LRH-1
SUMOylation in liver cells, it is tempting to speculate that
different physiological and/or pharmacological cues could
trigger specific posttranslational modifications in LRH-1, which
in turn could recruit specific corepressor complexes.
Several studies have identified natural or synthetic LRH-1 ac-
tivators and inhibitors (Ingraham and Redinbo, 2005). A recent
study has identified the unusual phospholipid dilauroyl phospha-
tidylcholine as an LRH-1 ligand (Lee et al., 2011b). Future studies
should test whether ligand activation, posttranslational modifi-
cations such as SUMOylation, and coregulator recruitment are
interconnected. The tissue and context-specific nature of such
effects may offer an ideal therapeutic window for activating a
receptor and exploit beneficial effects, without causing adverse
effects that are common with NR therapeutics (Marciano et al.,
2014). In this context, it is important to point out that the biolog-
ical effects of LRH-1 K289R cannot be compared to those
induced by a gain-of-function of LRH-1 or by a potential drug
that would enhance the activity of LRH-1 in a broader manner.
In fact, the Lrh-1 K289R mice show increased activation of
selected LRH-1 target genes, whereas other targets are not
affected. The Lrh-1 K289R mice also seem to display no effects
on RCT in the gut, most likely because LRH-1 and PROX-1 are
not coexpressed in the same cells of the crypt-villus epithelium
(Botrugno et al., 2004) or because of the low abundance of
PROX-1 in the intestinal mucosa (Figure 6C). Likewise, no
changes on Scarb1 gene expression could be detected in mac-
rophages (Figure S4E). Such a restriction of the effects of LRH-1c.
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target genes, may be the key to drive only antiatherogenic ef-
fects of LRH-1. A better understanding into how SUMOylation
of LRH-1 and ensuing coregulator recruitment can bemodulated
will be instrumental and may provide opportunities for pharma-
cological intervention to combat common diseases, such as
atherosclerosis.
EXPERIMENTAL PROCEDURES
Animal Studies
The generation of the Lrh-1 K289R mouse model is described in detail in the
Supplemental Experimental Procedures. Congenic C57Bl/6J Lrh-1 WT or
Lrh-1 K289R mice were crossbred with congenic C57Bl/6J Ldlr knockout
mice in order to generate Ldlr/ Lrh-1 WT (LL-WT) or Ldlr/ Lrh-1 K289R
(LL-K289R) mice. LL-WT and LL-K289Rmice were kept on an HCD (1.25% to-
tal cholesterol, Harlan TD.94059) for 14 weeks starting at the age of 8 weeks.
Similarly, congenic C57Bl/6J Lrh-1hep/ and Lrh-1hep+/+ mice (Oosterveer
et al., 2012) were crossbred with Ldlr/ mice in order to generate Ldlr/
Lrh-1hep+/+ (Ld-WT) or Ldlr/ Lrh-1hep/ (Ld-LKO) mice and fed a HCD for
12 weeks. All animal procedures were approved by the Swiss authorities
(Canton of Vaud, animal protocols ID #2561 and #2768) and performed in
accordance with our institutional guidelines.
Site-directed mutagenesis, subcellular fractionation of liver tissue, immuno-
precipitation (IP), Coimmunoprecipitation (CoIP), and western blotting are
explained in the Supplemental Experimental Procedures.
Protein Alignment
All protein alignments were performed with the standard Geneious (Blosum62
matrix) or ClustalW (BLOSUM matrix) algorithm from the Geneious software
(http://www.geneious.com).
Gene Expression and Analysis
RNA was extracted from the livers and jejunums of ad libitum fed Lrh-1 WT
(n = 7) and Lrh-1 K289R (n = 7) mice and from liver of ad libitum fed Lrh-
1hep+/+ (n = 8) and Lrh-1hep/ (n = 8) mice with TRIZOL (Invitrogen) and
purified with the RNeasy Cleanup Kit for Microarray Analysis (QIAGEN). For
quantitative RT-PCR (qRT-PCR), cDNA was generated with the QuantiTect
Reverse Transcription Kit (QIAGEN) and analyzed by qPCR with a LightCycler
480 Real-Time PCRSystem (Roche), and the primers are listed in the Table S2.
Expression data were normalized to 36B4 or B2M mRNA levels. Microarray
analysis was performed with the Affymetrix MouseGene 1.0 ST or Affymetrix
MouseGene 2.0 ST array and normalized with the robust multiarray average
method. A table of reciprocally regulated transcripts is provided in Table S1.
Venn diagram analysis and heatmaps were performed with GENE-E (http://
www.broadinstitute.org/cancer/software/GENE-E/index.html). For the Venn
diagram, the overlap of nominally significantly changed genes (p < 0.05 and
fold changeR 1.5) among the groups was analyzed.
Chromatin Immunoprecipitation
ChIP analysiswas performed as described previously withminormodifications
(Duggavathi et al., 2008). DNA was purified with the PCR Clean-up extrac-
tion kit (Macherey-Nagel), after which qPCR was performed as described
previously (Mataki et al., 2007). Data were normalized to the input (fold differ-
ences = 2(Ct sample  Ct input)). ChIP primer sequences are listed in Table S3.
Lipoprotein Separation
Pooled plasma samples were subjected to fast protein liquid chromatography
gel filtration with a Superose 6 Column (GE Healthcare). Individual fractions
were assayed for cholesterol and triglyceride concentrations with commer-
cially available enzymatic assays (Roche).
Hepatic Lipid Analyses
Hepatic lipids were extracted according to the Bligh and Dyer (1959) protocol.
Triglyceride and cholesterol contents in plasma and hepatic lipid fractions
were quantified with enzymatic assays (Roche).CellCholesterol Uptake and LPS Stimulation of Peritoneal Macrophages
Thioglycolate-elicited peritoneal macrophages were harvested, cultured, and
starved in vitro and then loaded with 50 mg/ml DiI-labeled acetylated LDL for
4 hr in order to assess the cholesterol uptake or 10 ng/ml LPS for 4 hr in order
to analyze the expression of inflammatory markers.
Reverse Cholesterol Transport
RCT protocol was adapted from Meissner et al. (2010). In brief, thioglycolate-
elicited mouse peritoneal macrophages were harvested, cultured in vitro,
loaded with 50 mg/ml acetylated LDL and 3 mCi/ml 3H-cholesterol for 24 hr,
and equilibrated in RPMI 1640 medium containing 1% penicillin/streptomycin
and 0.2% BSA for 6 hr. For in vivo RCT, two million labeled LL-WT macro-
phages were injected intraperitoneally into recipient LL-WT or LL-K289R
mice. Mice were sacrificed 48 hr postinjection, and plasma, liver, gallbladder,
and feces were stored at 80C until further analysis. Counts within liver were
determined after the solubilization of the tissue. Fecal samples were dried,
weighed, and thoroughly ground. Then, aliquots were separated into bile
acid and neutral sterol fractions prior to liquid scintillation counting.
Bile Flow and Bile Composition
Bile duct cannulation was performed as described previously (Kruit et al.,
2005) with LL-WT and LL-K289R mice. In brief, hepatic bile was collected
for 30 min from the common bile duct via cannulation of the gallbladder, and
bile flow was determined gravimetrically assuming a density of 1 g/ml for
bile. Bile composition was analyzed by high performance liquid chromatog-
raphy (HPLC) tandem mass spectrometry as described previously (Mataki
et al., 2007).
Primary Cell Culture
Primary hepatocytes from hepatocyte-specific Lrh-1hep/mice were isolated
with LiberaseBlendzyme (Roche) perfusion as described previouslywithminor
modifications (Ryu et al., 2011). Lrh-1hep/ hepatocytes were plated in Dul-
becco’s modified Eagle’s medium 4.5 g/l glucose with 10% fetal bovine
serum. Cells were infected with an adenovirus expressing LRH-1 WT or
LRH-1 K289R 4 hr after plating followed by transfection of a Prox1 plasmid
with Lipofectamine 2000 (Invitrogen). Cells were lysed 48 hr postinfection
and used for subsequent analysis.
Reporter Assays
Transient transfections in HEK293T cells were performed with Lipofectamine
2000 (Invitrogen) or JetPEI (Polyplus) as previously described (Oosterveer
et al., 2012). In brief, cells were transfected with pTK-GL3 reporter constructs
driven by a heterologous promoter consisting of multiple consensus LRH-1
response elements (pGL3::(LRHRE)5-TK-LUC) in the presence of either
pCMX::LRH-1 WT or the KR mutant constructs. Luciferase activities were
measured 24 hr posttransfection and normalized to b-galactosidase activities.
Immunohistochemistry
En face plaque analysis was performed on thoraco-abdominal aortae that
were fixed with 10% paraformaldehyde overnight and then stained with Oil-
Red O (Stein et al., 2010). Aortic sinuses were cut into 5-mm-thick serial cryo-
sections and stained with Sirius Red in order to measure necrotic core size,
cap thickness, and collagen content (Stein et al., 2010). Means were taken
from n = 6 mice per genotype, and three serial cryosections were evaluated
from each mouse.
Statistical Analyses
Data are expressed as means ± SEM. Analysis of en face atherosclerotic pla-
que content and bile excretion rates was carried out with Mann-Whitney U
tests. Comparison of differences between two groups of other experiments
was assessed with unpaired two-tailed Student’s t tests. Multiple group com-
parisonswere assessedbyone-wayANOVAandBonferonni post hoc tests. p<
0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
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